Results 41 to 50 of about 270,350 (354)
This review highlights recent advances in microfluidic technologies for modeling human aging and age‐related diseases. It explores how organ‐on‐chip platforms improve physiological relevance, enable rejuvenation strategies, facilitate drug screening, detect senescent cells, and identify biomarkers.
Limor Zwi‐Dantsis+5 more
wiley +1 more source
Background In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy.
Milind Y. Desai+10 more
doaj +1 more source
Introduction Hypertension affects 40%–60% of adults with hypertrophic cardiomyopathy (HCM), the most common inherited cardiac condition. It can be a diagnostic confounder for HCM, contributing to delayed diagnosis.
Daniele Massera+8 more
doaj +1 more source
Supplemental Digital Content is available in the text. Background: Pathogenic variants in MYBPC3, encoding cardiac MyBP-C (myosin binding protein C), are the most common cause of familial hypertrophic cardiomyopathy.
A. Helms+22 more
semanticscholar +1 more source
Abstract α‐Chiral amines are versatile building blocks for the asymmetric synthesis of optically pure high‐added‐value chemicals, including pharmaceuticals, agrochemicals, and natural products. Herein, we report a one‐pot, two‐step sequential deracemization of racemic sec‐alcohols to optically enriched primary amines throught a photo‐biocatalytic ...
Natalia Antos+5 more
wiley +1 more source
Non‐Invasive Diagnosis of Hypertrophic Cardiomyopathy by Breath
The use of sensor technologies for the diagnosis of hypertrophic cardiomyopathy (HCM) by identification of volatile organic compounds (VOCs) in breath samples. By combining gas chromatography‐mass spectrometry (GC‐MS) and electronic nose (eNose) platforms, specific VOC patterns associated with HCM are detected and analyzed.
Yael Hershkovitz‐Pollak+5 more
wiley +1 more source
[2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy].
© 2015, Silicea-Poligraf. All Rights Reserved. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Perry M. Elliott+19 more
semanticscholar +1 more source
NEU1, a key regulator of glycolysis, is markedly upregulated following DOX treatment. This upregulation is attributed to HIF1α’s transcriptional repression, requiring intricate interactions with NRF2. Increased NEU1 facilitates SIRT1 lysosomal degradation, contributing to aberrant glycolytic phenotype and cardiac damage.
Ting Gao+13 more
wiley +1 more source
Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy
Background: Development of advanced heart failure (HF) symptoms is the most common adverse pathway in hypertrophic cardiomyopathy (HCM) patients. Currently, there is a limited ability to identify HCM patients at risk of HF.Objectives: In this study, we ...
Ahmed S. Fahmy+5 more
doaj +1 more source
This work identifies fine‐tuning the expression of PIEZO1 as a critical molecular mechanism underlying the treatment of myocardial infarction by mechanically adapted cardiac patches, which can support the clinical translation of cardiac patch devices.
Yuwen Lu+18 more
wiley +1 more source